161 related articles for article (PubMed ID: 37838624)
1. Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach.
Chen L; Yao N; Yang H; Zhang S; Zhang K
Cancer Chemother Pharmacol; 2024 Feb; 93(2):107-119. PubMed ID: 37838624
[TBL] [Abstract][Full Text] [Related]
2. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases.
Liang F; Zhang Y; Xue Q; Zhang X
Sci Rep; 2024 Jun; 14(1):12736. PubMed ID: 38830973
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.
Djebli N; Buchheit V; Parrott N; Guerini E; Cleary Y; Fowler S; Frey N; Yu L; Mercier F; Phipps A; Meneses-Lorente G
Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):779-791. PubMed ID: 34495458
[TBL] [Abstract][Full Text] [Related]
4. Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib.
Li B; Liu S; Feng H; Du C; Wei L; Zhang J; Jia G; Wu C
Front Pharmacol; 2023; 14():1234262. PubMed ID: 38074113
[No Abstract] [Full Text] [Related]
5. Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
Seo SW; Han DG; Choi E; Park T; Byun JH; Cho HJ; Jung IH; Yoon IS
Biomed Pharmacother; 2022 Feb; 146():112520. PubMed ID: 34902744
[TBL] [Abstract][Full Text] [Related]
6. Prediction of drug-drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.
Jia G; Ren C; Wang H; Fan C
BMC Pharmacol Toxicol; 2024 Jan; 25(1):4. PubMed ID: 38167223
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
Xu L; Yu S; Liu H; Yi B; Wang G; Liu Y
Eur J Clin Pharmacol; 2022 Sep; 78(9):1435-1446. PubMed ID: 35680661
[TBL] [Abstract][Full Text] [Related]
8. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
10. Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases.
Salifu EY; Issahaku AR; Agoni C; Ibrahim MAA; Manimbulu N; Soliman MES
Cell Biochem Biophys; 2022 Mar; 80(1):11-21. PubMed ID: 35040089
[TBL] [Abstract][Full Text] [Related]
11. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
[TBL] [Abstract][Full Text] [Related]
12. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
13. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Frampton JE
Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
[TBL] [Abstract][Full Text] [Related]
14. Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach.
Liang F; Zhang Y; Xue Q; Yao N
Front Pharmacol; 2024; 15():1363259. PubMed ID: 38500771
[No Abstract] [Full Text] [Related]
15. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G; Bentley D; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Brink A; Djebli N; Mercier F; Buchheit V; Phipps A
Invest New Drugs; 2021 Jun; 39(3):803-811. PubMed ID: 33462752
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G
Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models.
Li C; Chen L; Li L; Chen W
Eur J Pharm Sci; 2023 Oct; 189():106564. PubMed ID: 37586436
[TBL] [Abstract][Full Text] [Related]
20. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]